FOR: ONDINE BIOPHARMA CORPORATION
TSX, AIM SYMBOL: OBP
December 16, 2009
Ondine Biopharma Corporation
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 16, 2009) - Ondine Biopharma Corporation
(TSX:OBP)(AIM:OBP) ("Ondine" or the "Company") today announces the following transactions by a
Director of the Company, by the Director's family, and by a charitable foundation of which the
Director and the Director's spouse are directors, and the aggregate ownership interest of the
Director's family and the charitable foundation in the Company:
/T/
Name Carolyn Cross
Relationship to the Company Director, Chairman and CEO
Date the transaction was
reported to the Company December 10, 2009
Date of trade December 10, 2009
Nature of the transaction Acquisition carried out in the market
Type of security Common shares
Number of securities acquired 1,000,000
Price per security Cdn. $0.035
Nature and extent of the above's
interest in the transaction 100% direct ownership interest
Number of shares held in the
Company by the Director immediately
subsequent to completion of
the transaction 5,107,510
Percentage direct ownership in the
Company of the Director immediately
subsequent to completion of
the transaction 4.98%
Number of shares held in the
Company by the Director's family
immediately subsequent to completion
of the transaction, together with
the shares held by the Courthill
Foundation disclosed below 16,721,133
Percentage ownership in the Company
by the Director's family immediately
subsequent to completion of the
transaction, together with the
holdings of the Courthill Foundation 16.31%
Close period No
Name Courthill Foundation
Relationship to the Company A charitable foundation in which
Carolyn Cross and her husband
are directors
Date the transaction
was reported to the Company December 15, 2009
Date of trade December 15, 2009
Nature of the transaction Acquisition carried out privately
Type of security Common shares
Number of securities acquired 8,866,356
Price per security Cdn. $0.065
Nature and extent of the
above's interest in the transaction 100% direct ownership interest
Number of shares held directly in
the Company by the foundation
immediately subsequent to
completion of the transaction 8,866,356
Percentage ownership in the
Company by the foundation immediately
subsequent to completion of
the transaction 8.65%
Close period No
Name Cross Family Trust
Relationship to the Company A trust in which the beneficiaries
are family of Carolyn Cross
Date the transaction
was reported to the Company December 15, 2009
Date of trade December 15, 2009
Nature of the transaction Disposition carried out privately
Type of security Common shares
Number of securities disposed 8,866,356
Price per security Cdn. $0.065
Nature and extent of the
above's interest in the transaction 100% direct ownership interest
Number of shares held directly
in the Company by the trust
immediately subsequent to
completion of the transaction Nil
Percentage direct ownership in
the Company by the trust
immediately subsequent to
completion of the transaction Nil
Close period No
/T/
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
Ondine Biopharma Corporation
Carolyn Cross
Chairman and Chief Executive Officer
(604) 669-0555
ccross@ondinebiopharma.com
OR
Canaccord Adams Ltd.
Ryan Gaffney
Nominated Adviser
+4420 7050 6500
-0-
Ondine Biopharma Corporation